Eli Lilly raises 2026 outlook as Mounjaro and Zepbound sales accelerate

Lilly reported adjusted earnings of $8.55 per share for the quarter, well above the consensus estimate of $6.66. Net sales reached $19.79 billion, eclipsing the $17.62 billion forecast. The top‑line beat was driven primarily by a 65% jump in volume, which more than offset a 13% decline in realized prices caused by recent rebate and discount adjustments. Overall, the "Key Products" segment—comprising the company’s blockbuster GLP‑1 drugs and its immunology, oncology and neuroscience lines—generated $13.4 billion, reflecting a 160% expansion in those therapeutic areas.

Mounjaro and Zepbound continued to dominate Lilly’s revenue stream. Mounjaro’s sales climbed 125% to $8.7 billion, with U.S. revenue rising 59% to $4.2 billion despite lower average selling prices. Zepbound, the newer GLP‑1 weight‑loss agent, posted a 79% increase to $4.1 billion in U.S. sales, also feeling the drag of price cuts tied to the company’s cash‑pay pricing strategy. A one‑time adjustment for rebates helped cushion the impact of those lower realized prices, but the sheer volume growth underscores the durability of demand for GLP‑1 therapies.

The quarter also featured a regulatory milestone: the FDA approved Foundayo, the first oral GLP‑1 pill that can be taken without food or water restrictions. Management highlighted the drug’s potential to broaden the addressable market for GLP‑1 treatments, especially among patients who struggle with injectable regimens. At the same time, Lilly announced two strategic acquisitions—Kelonia Therapeutics for up to $7 billion and Ajax Therapeutics for up to $2.3 billion—aimed at bolstering its gene‑delivery platform and expanding its oncology pipeline. These deals signal a continued focus on diversifying revenue beyond the weight‑loss franchise.

Guidance for fiscal 2026 was upgraded across the board. Adjusted earnings are now projected at $35.50‑$37.00 per share, up from the prior $33.50‑$35.00 range, while sales are expected to fall between $82 billion and $85 billion, a $2 billion increase from the earlier outlook. Both figures sit slightly above the consensus forecasts of $34.55 per share and $82.1 billion in sales, respectively. Analysts have responded by lifting their median price target to $1,244.68, implying roughly 33% upside from the current $934.34 market price.

The market reacted positively, with LLY shares jumping 9.2% to $929.38 in early trading and settling near $934 later in the day. Technical indicators suggest the stock remains in a bullish phase: it trades above its 200‑day moving average, the RSI hovers around the neutral 49 level, and relative volume is more than double its 20‑day average. However, the stock is still 17.6% below its 52‑week high of $1,133.95 and has underperformed the S&P 500 by roughly 18% year‑to‑date, reflecting broader sector weakness and pricing headwinds.

Lilly’s performance must be viewed against the backdrop of an increasingly crowded GLP‑1 market. Competitors such as Novo Nordisk, Pfizer and AstraZeneca are racing to launch their own oral and next‑generation agents, which could intensify pricing pressure. At the same time, the global appetite for obesity and diabetes treatments remains robust, driven by rising prevalence and expanding insurance coverage. Lilly’s ability to sustain volume growth while managing price erosion will be a key determinant of its long‑term earnings trajectory.

For investors, the quarter delivers a clear mix of upside catalysts and cautionary signals. The earnings beat, guidance lift, and Foundayo approval point to continued top‑line momentum, while the acquisitions broaden the pipeline beyond GLP‑1s. Yet, the company’s reliance on price‑sensitive weight‑loss drugs and the looming competitive landscape introduce risk. Stakeholders should monitor pricing trends, the commercial rollout of Foundayo, and integration progress of Kelonia and Ajax as the next earnings season approaches.